AstraZeneca’s cancer immunotherapy Imfinzi has been granted orphan drug status as a treatment for small cell lung cancer (SCLC).
The FDA has granted Imfinzi (Durvalumab) an Orphan Drug Designation (ODD) as a treatment for SCLC which accounts for around 15% of all lung cancer diagnoses.
SCLC is the most aggressive form of lung cancer with only 6% of patients living for more than 5 years. The FDA grants ODDs to drugs which treat diseases which affect fewer than 200,000 people in the United States.
